TB treatment outcomes among TB-HIV co-infections in Karnataka, India: how do these compare with non-HIV tuberculosis outcomes in the province?

BMC Public Health

Ayesha De Costa¹  Bharat Rewari³  Anita Shet¹  Balaji Naik²  Suresh Shastri⁴ 

[1] Division of Global Health, Karolinska Institutet, Stockholm, Sweden;Revised National TB Control Program, Bangalore, Karnataka, India;National AIDS Control Program, New Delhi, India;Karnataka State AIDS Prevention Society, Bangalore, Karnataka, India

关键词: HIV TB co-infection India program epidemiology treatment outcomes;   

Others  :  1161795
DOI  :  10.1186/1471-2458-13-838

 received in 2012-09-11, accepted in 2013-09-04,  发布年份 2013

【 摘 要 】

Background

India accounts for 23% of the global incidence of TB cases; it also has an estimated 2.3 million HIV infections. Of the 2 million TB incident cases, 5% occurred in HIV infected persons. The country has large national TB and HIV control programs. This paper describes characteristics of TB-HIV co-infection cases registered under the program in Karnataka province, India. Treatment outcomes for coinfected patients are compared with those for TB patients in the province.

Methods

Program reports from the National AIDS Control program and the National TB control program for Karnataka province (a high HIV prevalence state, population 61 million) were analysed. Data from patients registered in each program in 2010–2011 was studied.

Results

Of the 6,480 adult co-infections, a third occurred in women; 78% of patients were initiated on ART. Among the cohort 73% had pulmonary TB, and 46% reported sputum positivity for acid fast bacilli. Treatment success among co-infected patients not on ART (54%) were significantly lower compared to those already on ART (80%); death and default rates were higher in the non-ART group. Treatment success proportions (75%) for the co-infected patients were similar to those for the 51,966 patients registered under the TB program. Death rates among co-infected patients (15%) were twice as high as for TB patients under the program, though default and failure rates were lower.

Conclusion

Co-infected patients already on ART demonstrated better TB outcomes in than those not on ART. Compared to those with TB only, co-infected patients had similar TB treatment success rates and lower rates of treatment default and failure. Integration of TB-HIV collaborative activities will strengthen our battle to control TB and HIV globally.

【 授权许可】

   
2013 Shastri et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Havlir DV, Getahun H, Sanne I, Nunn P: Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008, 300:423-430.
• [2]Toossi Z: Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003, 188:1146-1155.
• [3]Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, et al.: Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 2000, 4:839-844.
• [4]World Health Organization: Global tuberculosis control: WHO report 2011. Geneva: World Health Organization; 2011:viii. 246 p. p
• [5]Dewan PK, Gupta D, Williams BG, Thakur R, Bachani D, et al.: National estimate of HIV seroprevalence among tuberculosis patients in India. Int J Tuberc Lung Dis 2010, 14:247-249.
• [6]UNAIDS: UNAIDS World AIDS day report 2011. 2011.
• [7]UNAIDS: United Nations General Assembly Special Session (UNGASS) Country Progress report 2010. India; 2010.
• [8]World Health Organization: Global tuberculosis control— surveillance, planning, financing: country profile India. Geneva: WHO; 2008:109-112.
• [9]Government of Karnataka, Karnataka State AIDS Prevention Society: Government of Karnataka KSAPS. http://karhfw.gov.in/ksaps/HIVKarnatka.html webcite
• [10]Government of India - Central TB Division: Technical and Operations Guidelines for Tuberculosis Control. New Delhi; 2005.
• [11]Government of India: Managing the RNTCP programme in your area, a training course, Module(1-4). New Delhi: Central TB division, Directorate generate of Health Services, Ministry of Health and Family Welfare; 2005:1-3.
• [12]Swaminathan S, Nagendran G: HIV and tuberculosis in India. J Biosci 2008, 33:527-537.
• [13]Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatittham W, et al.: HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. Int J Infect Dis 2009, 13:722-729.
• [14]Tayler-Smith K, Zachariah R, Manzi M, Kizito W, Vandenbulcke A, et al.: Antiretroviral treatment uptake and attrition among HIV-positive patients with tuberculosis in Kibera, Kenya. Trop Med Int Health 2011.
• [15]Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al.: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
• [16]Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S: Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43:42-46.
• [17]Domingos MP, Caiaffa WT, Colosimo EA: Mortality, TB/HIV co-infection, and treatment dropout: predictors of tuberculosis prognosis in Recife, Pernambuco State, Brazil. Cad Saude Publica 2008, 24:887-896.
• [18]Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al.: Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
• [19]Government of India - Dept of AIDS Control: Revised guidelines on initiation of ART in adults and adolescents. New Delhi: National AIDS Control Organisation; 2011. T-11020/36/2005-NACO (ART) T-11020/36/2005-NACO (ART)
• [20]Kumar AM, Gupta D, Rewari BB, Bachani D, Mohammed S, et al.: Will adoption of the 2010 WHO ART guidelines for HIV-infected TB patients increase the demand for ART services in India? PLoS One 2011, 6:e24297.
• [21]De Cock KM, Soro B, Coulibaly IM, Lucas SB: Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992, 268:1581-1587.
• [22]Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, et al.: Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997, 155:996-1003.
• [23]Falvo JV, Ranjbar S, Jasenosky LD, Goldfeld AE: Arc of a Vicious Circle: Pathways Activated by Mycobacterium tuberculosis That Target the HIV-1 Long Terminal Repeat. Am J Respir Cell Mol Biol 2011, 45:1116-1124.
• [24]Peloquin CA, MacPhee AA, Berning SE: Malabsorption of antimycobacterial medications. N Engl J Med 1993, 329:1122-1123.
• [25]Swaminathan S, Padmapriyadarsini C, Narendran G: HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010, 50:1377-1386.